An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS) Abstract #1684

Introduction: In ELECT, LAN 120mg every 4 weeks significantly reduced octreotide rescue therapy use for symptomatic CS control vs placebo (PBO).
Aim(s): This patient centric analysis explores the treatment effect on patient benefit during this trial.
Materials and methods: The analysis used all patient-reported outcomes collected during the double-blind phase of ELECT: daily diarrhea and flushing symptoms, octreotide rescue use and EORTC QLQ-C30 and QLQ-GINET.21 questionnaires at baseline and week 12. We applied principal component (PC) analysis on the baseline data to identify independent variable clusters, identified summary measures that were highly correlated to these PCs, derived minimum clinical important differences (MCID) and performed a responder analysis.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: George Camba
Keywords: SSA, carcinoid, symptoms

To read results and conclusion, please login ...

Further abstracts you may be interested in

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome
Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD PhD Kristina Linder Ekberg
Authors: Linder Ekberg K
#943 SSA Therapy for Patients with Bronchial Carcinoids (BC) in the Community Setting
Introduction: SSA show antitumoral effect in GEP-NETs in 2 phase III trials, PROMID and CLARINET. However, patients (pts) with BC were not included in these studies.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Carlos Lopez Lopez
Keywords: bronchial, carcinoid, SSA
#1925 SSA-, H1, H2- and Leukotriene Receptor Blockade Eliminates Handicapping Symptoms from Atypical Carcinoid Syndrome
Introduction: The patient is a female, 59 yrs , previously healthy except from mild allergic rinitis since 12 years of age and at 49 a suspected anaphylaxis after hazelnut intake.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: MD PhD Kristina Linder Ekberg
Keywords: PGD2
#2097 Oral Ondansetron Offers Effective Symptomatic Bridging for Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin analogues (SSA) are standard for symptomatic patients with neuroendocrine tumours (NETs). However, most patients experience tachyphylaxis, and limited options exist for this refractory carcinoid syndrome (RCS). Recently, ondansetron has been associated with reduction of bowel movement in a small series.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr. Barbara Kiesewetter
Authors: Kiesewetter B, Duan H, Haug A, Riss P, ...
#2208 High Hepatic Tumor Burden and History of Cardiovascular Comorbidities Are Associated with Carcinoid Heart Disease: A Multicenter and Multinational Study
Introduction: While 5HT is considered the main causative agent for carcinoid heart disease (CHD, not all pts with elevated 24h-urinary 5HIAA (u5HIAA) develop CHD.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof Rachel Riechelmann